Purdue University-linked companies operating the in renewable energy, sustainable transport and oncology sectors are among those to have secured $20,000 in initial funding.

The pharmaceutical firm more than doubled the size of its Boehringer Ingelheim Venture Fund, which has scored exits in two nine-figure acquisitions.

GV and Celgene-backed Armo BioSciences has filed to raise up to $86.3m in an offering that will fund clinical tests for its lead immuno-oncology candidate.

Novartis participated in a series B round that raised $50m for Pear Therapeutics, the creator of a software platform that assists substance abuse treatment.

Microsoft joined a consortium including existing investors GV and WuXi NextCode to take the biomedical data platform's overall financing to $105m.

Johns Hopkins University spinout NexImmune has raised series A funding a year after being acquired by a consortium of individual investors in January 2017.

The Novo and Merck-backed pruritus therapy developer has filed to raise up to $97.8m, having already secured almost $110m in VC funding.

Biogen-backed Duchenne muscular dystrophy (DMD) treatment developer Solid Biosciences has filed to raise up to $100m.

Qualcomm's corporate venturing arm has spent a third of its $150m India fund and plans to make six investments in the country per year.

BioBay, the industrialisation hub where contract pharmaceutical services provider CMab Biopharm is located, is among its investors.